Sahajanand Medical Technologies Reports Strong Q2 and H1 FY27 Performance
Sahajanand Medical Technologies Limited · Investor Presentation · 05 Nov 2026, 10:51 pm
Sahajanand Medical Technologies Reports Strong Q2 and H1 FY27 Performance In its first results post-listing on 23rd Oct'26, Sahajanand Medical Technologies delivered record Q2 FY27 performance, with revenue rising 24.7% YoY to ₹3,734 mn, EBITDA increasing 36.6% YoY to ₹656 mn (margin at 17.6%), and PAT growing 26.6% YoY to ₹265 mn. For H1 FY27, revenue expanded 24.9% YoY to ₹7,251 mn, driven by 37.1% YoY growth in RoW markets. Annualised ROCE and ROE improved to 16.7% and 11.2%, respectively, while the cash conversion cycle shortened by 10 days YoY to 128 days.
Original exchange filing (PDF)
More announcements from Sahajanand Medical Technologies Limited
- Schedule of Analyst/Investor Meet · 11 Nov 2026
- Transcript of Earnings Call for Q2 & H1 FY27 Financial Results held on Thursday, November 05, 2026. · 08 Nov 2026
- As per SEBI(LODR) Regulations, 2015- submission of audio recording of Earnings call held on 05 November 2026 · 06 Nov 2026
- The Board of Directors of the Company at it Meeting held today has approved appointment of M/s. Amit Jaste & Associates, Company Secretaries as Secretarial Auditor of the Company. · 06 Nov 2026
- Dear Sir/Ma''am- The Board of Directors of the Company has approved investment by wholly owned subsidiary company in SNP Medical Corp. · 05 Nov 2026
- Outcome of the Board Meeting dated November 5, 2026 · 05 Nov 2026
- Results- Unaudited financial Results for the period ended 30th September 2026 · 05 Nov 2026
- Sahajanand Medical Technologies Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
